Why the study?
Bicistronic transgene expression using IRES elements is widely used, but the performance of encephalomyocarditis virus (EMCV) IRES-containing rAAV6 vectors in hematopoietic cells needed evaluation.
Does EMCV IRES affect transgene expression in hematopoietic cells?
Does EMCV IRES affect transgene expression in hematopoietic cells?
EMCV IRES dramatically reduces transgene expression in hematopoietic cells when located between a promoter and transgenes, suggesting alternative strategies like the 2A system should be used for bicistronic expression.
EMCV IRES may suppress transgene expression in hematopoietic cells; leaves open optimal bicistronic vector design for preclinical research.
Bicistronic transgene expression mediated by internal ribosome entry site (IRES) elements has been widely used. It co-expresses heterologous transgene products from a message RNA driven by a single promoter. Hematologic gene delivery is a promising treatment for both inherited and acquired diseases. A combined strategy was recently documented for potential genome editing in hematopoietic cells. A transduction efficiency exceeding ~90% can be achieved by capsid-optimized recombinant adeno-associated virus serotype 6 (rAAV6) vectors. In this study, to deliver an encephalomyocarditis virus (EMCV) IRES-containing rAAV6 genome into hematopoietic cells, we observed that EMCV IRES almost completely shut down the transgene expression during the process of mRNA-protein transition. In addition, position-dependent behavior was observed, in which only the EMCV IRES element located between a promoter and the transgenes had an inhibitory effect. Although further studies are warranted to evaluate the involvement of cellular translation machinery, our results propose the use of specific IRES elements or an alternative strategy, such as the 2A system, to achieve bicistronic transgene expression in hematopoietic cells.
No takes yet. Share an insight, caveat, or question.
Zheng et al. (2019) studied this question.